Minister reluctant to give ‘false hope’ on DMD drug
Health Minister, Mike Nesbitt, says that it would be “inappropriate” for him to intervene in the Belfast Trust's decision to not administer givinostat.
The drug, used to treat Duchenne muscular dystrophy (DMD), came to prominence after Newry lad Alfie Pentony told radio listeners that it was "cruel" that he could not use it.


The Minister was questioned about what steps are being taken to ensure that the drug will be available through an early access programme by Alliance MLA John Blair, whose late brother Adrian also had Duchenne.
Mr Nesbitt told him that one of his duties is to ensure that Northern Ireland has timely access to clinically effective and cost-effective medicines.


"We do that through a formal link with the National Institute for Health and Care Excellence (NICE). As givinostat is a new treatment, routine access in the Health and Social Care system is based on the outcome of considerations from NICE. NICE is currently evaluating givinostat. Final guidance is not expected until July,” he explained.
"There is a route through an early access programme ahead of NICE decisions, but responsibility for participation in those EAPs lies with the trusts. A compassionate use scheme such as that works well for therapies and conditions in which no close monitoring of patients is required. However, when monitoring is required, which is the case for givinostat, clinical centres need additional resources... to undertake the monitoring safely and sustainably. Although medicines under EAPs are typically provided for free, additional implementation costs will fall to the relevant trust, which is, in this case, the Belfast Trust. Having considered the resource required to administer givinostat safely and efficiently, the trust has advised that it is not able to facilitate this early intervention.
"It would be inappropriate for me or my Department to intervene in the trust's decision, as that risks undermining our well-established processes with NICE that ensure that our population has access to new medicines that have been demonstrated to be clinically effective and cost-effective. Should NICE recommend givinostat, my Department will consider it under the usual processes and endeavour to make the drug available as quickly as possible.”
Mr Nesbitt added that he did “not want to provide false hope”.
"It is up to NICE to decide whether it is safe to administer or recommend givinostat. NICE is a non-departmental public body. It is sponsored by the Department of Health and Social Care in London. It produces national guidance on the promotion of good health and the prevention and treatment of ill health. It makes its recommendations independently. As I have said previously, it would be entirely inappropriate of me to intervene with the Belfast Trust to try to expedite the matter, unfortunately.”
Newry & Armagh SDLP MLA, Justin McNulty said Alfie had “inspired us all with his impassioned and courageous campaign.
"Access to givinostat would dramatically improve outcomes for children such as Alfie. However, given the Minister's earlier comments, what action can his Department take to give hope to families such as Alfie's and others?” he asked.Mr Nesbitt said he had “to progress within the rules and recommendations and do so safely.
"The Belfast Trust provides a regional paediatric neuromuscular service through the Royal Belfast Hospital for Sick Children, and that would include the boy to whom the Member has referred.”